Inhaled Antibiotics Market Report 2025

The inhaled antibiotics market size has grown strongly in recent years. It will grow from $1.56 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to regulatory support and approvals, shift from systemic to targeted delivery, rise in antibiotic resistance, increase in respiratory infections.

The inhaled antibiotics market size is expected to see strong growth in the next few years. It will grow to $2.37 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to growing investments in research and development, expansion of clinical applications, increasing focus on personalized medicine, advancements in drug formulations, continued antibiotic resistance concerns. Major trends in the forecast period include continued innovation in formulations, patient-centric approach, increased research in respiratory health, shift towards targeted therapies, advancements in drug delivery systems.

The rising prevalence of respiratory diseases is anticipated to drive the growth of the inhaled antibiotics market in the coming years. Respiratory diseases harm the lungs and airways, making it difficult for individuals to breathe. Inhaled antibiotics improve lung function, help prevent a decline in lung health, prolong the intervals between exacerbations, and enhance the quality of life for patients with cystic fibrosis. For example, a report from the UK Health Security Agency, a government organization in the UK, indicated that the number of tuberculosis (TB) cases in England increased by 7% in the first half of 2023 compared to the same period in 2022. Thus, the rising incidence of respiratory diseases is a key factor driving the inhaled antibiotics market.

The growing demand within hospitals is expected to boost the inhaled antibiotics market in the future. Hospitals are healthcare facilities designed to provide medical treatment, care, and services to individuals who are ill or injured. Inhaled antibiotics are utilized in hospital settings, especially for treating respiratory infections, as they help minimize the impact on gut microbiota, tailor treatment plans, enhance patient compliance, and lower hospitalization rates. For instance, a report from the American Health Care Association, a nonprofit organization based in the US, noted that there were 6,129 hospitals in the United States in May 2023, marking a 0.591% increase from the 6,093 hospitals the previous year. Consequently, the rising demand in hospitals is fueling the growth of the inhaled antibiotics market.

Investments in the development of inhaled antibiotics represent a significant trend gaining traction in the inhaled antibiotics market. Major pharmaceutical companies are committing resources to the development of inhaled antibiotics to maintain their competitive edge. For example, in August 2023, Spexis AG, a biopharmaceutical company based in Switzerland, announced a $2.5 million capital commitment aimed at financing the U.S. commercialization of colistimethate sodium, an inhaled antibiotic intended for cystic fibrosis patients with Pseudomonas aeruginosa infections. This funding supports commercialization efforts projected at $90 million, with potential peak sales reaching $300 million. Additionally, it facilitates the initiation of a Phase III safety and efficacy study for the antibiotic's application in cystic fibrosis treatment.

Innovative products like Breyna are being strategically introduced by major players in the inhaled antibiotics market to drive revenue growth. Breyna, an inhalation aerosol combining formoterol fumarate dihydrate and budesonide, effectively manages symptoms associated with asthma and persistent lung diseases. Viatris Inc., in partnership with Kindeva Drug Delivery L.P., successfully launched Breyna in July 2023. This FDA-approved generic version of AstraZeneca's Symbicort is supplied as a metered-dose inhaler and comes in two strengths, catering to patients' varying needs, reflecting the market's focus on innovation and tailored therapeutic solutions.

In January 2024, Essential Pharma, a pharmaceutical company based in the UK, acquired Colobreathe from Teva Laboratories UK Limited for an undisclosed sum. This acquisition signifies Essential Pharma's entry into the rare disease sector, enhancing its portfolio with treatments specifically designed for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. With this deal, the company aims to secure ongoing access to essential medications throughout Europe. Teva Laboratories UK Limited is recognized as a UK-based manufacturer of inhaled antibiotics.

Major companies operating in the inhaled antibiotics market are Gilead Sciences Inc., Lupin Limited, Insmed Inc., Savara Inc., Joincare Pharmaceutical Group Industry Co. Ltd., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical Corporation, Altan Pharma Limited, Cipla Limited, Novartis AG, Bayer AG, Pfizer Inc., Aridis Pharmaceuticals, Bayer HealthCare, Nektar Therapeutics, Parion Sciences Inc., Zambon Group, Transave Inc., Alitair Pharmaceuticals, Synspira Therapeutics Inc., AIT Therapeutics Inc., Polyphor AG, OptiNose Inc.

North America was the largest region in the inhaled antibiotics market share in 2024. The regions covered in the inhaled antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhaled antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Inhaled antibiotics serve as medication specifically targeted for respiratory issues, effectively enhancing survival rates and contributing to improvements in lung function. These medications have proven instrumental in delaying lung function deterioration, extending intervals between exacerbations, and elevating overall quality of life.

Diverse types of inhaled antibiotics are available, including aerosol or metered dose inhalers, dry powder formulations, sprays, and other variations. The metered-dose inhaler (MDI) stands as a frequently utilized device for delivering inhaled respiratory medications. These antibiotics find applications across a spectrum of respiratory conditions like pneumonia, asthma, bronchitis, among others, catering to the needs of hospitals and various other healthcare settings.

The inhaled antibiotics market research report is one of a series of new reports that provides inhaled antibiotics market statistics, including inhaled antibiotics industry global market size, regional shares, competitors with an inhaled antibiotics market share, detailed inhaled antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the inhaled antibiotics industry. This inhaled antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhaled antibiotics market consists of sales of jet nebulizers, ultrasonic nebulizers, mesh inhalers, and soft mist inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.